Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Moxipraquine is a novel 8-aminoquinolone compound with anti-infective activity against Trypanosoma cruzi. Moxipraquine effectively inhibited parasitemia but did not eradicate infections in mice or guinea pigs. Moxipraquine was effective against experimental infections of Leishmania major, Lactobacillus mexicanus, and Lactobacillus brasiliensis, but was Ineffective.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 37,500 | |||
5 mg | 在庫あり | ¥ 89,500 | |||
10 mg | 在庫あり | ¥ 135,500 | |||
25 mg | 在庫あり | ¥ 216,500 | |||
50 mg | 在庫あり | ¥ 294,000 | |||
100 mg | 在庫あり | ¥ 397,000 | |||
500 mg | 在庫あり | ¥ 794,000 |
説明 | Moxipraquine is a novel 8-aminoquinolone compound with anti-infective activity against Trypanosoma cruzi. Moxipraquine effectively inhibited parasitemia but did not eradicate infections in mice or guinea pigs. Moxipraquine was effective against experimental infections of Leishmania major, Lactobacillus mexicanus, and Lactobacillus brasiliensis, but was Ineffective. |
In vivo |
Moxipraquine (5, 15, or 45 mg base/kg; oral; 14 days) was effective in suppressing parasitemia but did not eradicate the infection from mice or guinea pigs.[1] Moxipraquine (50 mg base/kg; oral; 5 times) was effective on experimental infections of Leishmania major, L. Mexicana mexicana, and L.brasiliensis panamensis but not L.b.brasiliensis.[1] |
分子量 | 414.58 |
分子式 | C24H38N4O2 |
CAS No. | 23790-08-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 18.33 mg/mL (44.22 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Moxipraquine 23790-08-1 Microbiology/Virology Antibiotic Inhibitor inhibitor inhibit